<DOC>
	<DOC>NCT00295750</DOC>
	<brief_summary>The study was a three-arm, active-control, multi-centre, parallel group study.</brief_summary>
	<brief_title>The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Main Patients, aged 18 years or over, with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated. Baseline testosterone &gt;1.5 ng/mL. Life expectancy of at least 12 months.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>